Overview
ANRO market data
Price History
ANRO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.50 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.13 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,374.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.02 – $29.70 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/B 3.66.
Company News
Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26Benzinga · Aug 13, 2026, 12:52 PM
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37Benzinga · Aug 13, 2026, 10:12 AM
Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) EstimateBenzinga · Aug 12, 2026, 8:19 PM
8-K filing — Alto Neuroscience, Inc. (ANRO)SEC EDGAR · Aug 12, 2026, 8:14 PM
Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/ShareBenzinga · Jul 13, 2026, 11:48 AM
Alto Neuroscience Intends To Accelerate And Expand Clinical Development Of ALTO-207, Including An Additional Planned Phase 3 Trial As Monotherapy For Treatment-Resistant DepressionBenzinga · Jul 13, 2026, 11:46 AM
Alto Neuroscience Publishes Trial Of Dopamine Agonist Pramipexole With Mood Disorders And Clinically Significant Anhedonia In Nature MediceBenzinga · Jun 15, 2026, 12:20 PM
Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36Benzinga · May 18, 2026, 5:10 PM